Association/NN
of/IN
TRAF1/NN
,/,
TRAF2/NN
,/,
and/CC
TRAF3/NN
with/IN
an/DT
Epstein-Barr/JJ
virus/NN
LMP1/NN
domain/NN
important/JJ
for/IN
B-lymphocyte/NN
transformation/NN
:/:
role/NN
in/IN
NF-kappaB/NN
activation/NN
./.

The/DT
Epstein-Barr/JJ
virus/NN
(/(
EBV/NN
)/)
transforming/VBG
protein/NN
LMP1/NN
appears/VBZ
to/TO
be/VB
a/DT
constitutively/RB
activated/VBN
tumor/NN
necrosis/NN
factor/NN
receptor/NN
(/(
TNFR/NN
)/)
on/IN
the/DT
basis/NN
of/IN
an/DT
intrinsic/JJ
ability/NN
to/TO
aggregate/VB
in/IN
the/DT
plasma/NN
membrane/NN
and/CC
an/DT
association/NN
of/IN
its/PRP$
cytoplasmic/JJ
carboxyl/NN
terminus/NN
(/(
CT/NN
)/)
with/IN
TNFR-associated/JJ
factors/NNS
(/(
TRAFs/NNS
)/)
./.
=====
We/PRP
now/RB
show/VBP
that/IN
in/IN
EBV-transformed/JJ
B/NN
lymphocytes/NNS
most/JJS
of/IN
TRAF1/NN
or/CC
TRAF3/NN
and/CC
5/CD
%/NN
of/IN
TRAF2/NN
are/VBP
associated/VBN
with/IN
LMP1/NN
and/CC
that/IN
most/JJS
of/IN
LMP1/NN
is/VBZ
associated/VBN
with/IN
TRAF1/NN
or/CC
TRAF3/NN
./.
=====
TRAF1/NN
,/,
TRAF2/NN
,/,
and/CC
TRAF3/NN
bind/VBP
to/TO
a/DT
single/JJ
site/NN
in/IN
the/DT
LMP1/NN
CT/NN
corresponding/VBG
to/TO
amino/NN
acids/NNS
(/(
aa/NNS
)/)
199/CD
to/TO
214/CD
,/,
within/IN
a/DT
domain/NN
which/WDT
is/VBZ
important/JJ
for/IN
B-lymphocyte/NN
growth/NN
transformation/NN
(/(
aa/NNS
187/CD
to/TO
231/CD
)/)
./.
=====
Further/JJ
deletional/JJ
and/CC
alanine/NN
mutagenesis/NN
analyses/NNS
and/CC
comparison/NN
with/IN
TRAF/NN
binding/NN
sequences/NNS
in/IN
CD40/NN
,/,
in/IN
CD30/NN
,/,
and/CC
in/IN
the/DT
LMP1/NN
of/IN
other/JJ
lymphycryptoviruses/NNS
provide/VBP
the/DT
first/JJ
evidence/NN
that/IN
PXQXT/S/NN
is/VBZ
a/DT
core/NN
TRAF/NN
binding/NN
motif/NN
./.
=====
The/DT
negative/JJ
effects/NNS
of/IN
point/NN
mutations/NNS
in/IN
the/DT
LMP1(1-231)/NN
core/NN
TRAF/NN
binding/NN
motif/NN
on/IN
TRAF/NN
binding/NN
and/CC
NF-kappaB/NN
activation/NN
genetically/RB
link/VBP
the/DT
TRAFs/NNS
to/TO
LMP1(1-231)-mediated/JJ
NF-kappaB/NN
activation/NN
./.
=====
NF-kappaB/NN
activation/NN
by/IN
LMP1(1-231)/NN
is/VBZ
likely/JJ
to/TO
be/VB
mediated/VBN
by/IN
TRAF1/TRAF2/NN
heteroaggregates/NNS
since/IN
TRAF1/NN
is/VBZ
unique/JJ
among/IN
the/DT
TRAFs/NNS
in/IN
coactivating/VBG
NF-kappaB/NN
with/IN
LMP1(1-231)/NN
,/,
a/DT
TRAF2/NN
dominant-negative/JJ
mutant/NN
can/MD
block/VB
LMP1(1-231)-mediated/JJ
NF-kappaB/NN
activation/NN
as/RB
well/RB
as/IN
TRAF1/NN
coactivation/NN
,/,
and/CC
30/CD
%/NN
of/IN
TRAF2/NN
is/VBZ
associated/VBN
with/IN
TRAF1/NN
in/IN
EBV-transformed/JJ
B/NN
cells/NNS
./.
=====
TRAF3/NN
is/VBZ
a/DT
negative/JJ
modulator/NN
of/IN
LMP1(1-231)-mediated/JJ
NF-kappaB/NN
activation/NN
./.
=====
Surprisingly/RB
,/,
TRAF1/NN
,/,
-2/CD
,/,
or/CC
-3/CD
does/VBZ
not/RB
interact/VB
with/IN
the/DT
terminal/JJ
LMP1/NN
CT/NN
aa/NNS
333/CD
to/TO
386/CD
which/WDT
can/MD
independently/RB
mediate/VBP
NF-kappaB/NN
activation/NN
./.
=====
The/DT
constitutive/JJ
association/NN
of/IN
TRAFs/NNS
with/IN
LMP1/NN
through/IN
the/DT
aa/NNS
187/CD
to/TO
231/CD
domain/NN
which/WDT
is/VBZ
important/JJ
in/IN
NF-kappaB/NN
activation/NN
and/CC
primary/JJ
B-lymphocyte/NN
growth/NN
transformation/NN
implicates/VBZ
TRAF/NN
aggregation/NN
in/IN
LMP1/NN
signaling/NN
./.